The company is scaling up manufacturing and commercial activities as it prepares to enter the U.S. market via the Food and Drug Administration’s de novo pathway.

Shortly after securing an FDA clearance last month for its simple, self-operated blood sample collection device, Tasso has teamed up with Catapult Health to help propel its device into people’s homes.